Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$2.12 -1.4%	$1.55	$1.11 ▼ $5.00	$564.22M	1.76	1.56 million shs	1.89 million shs
LJPC La Jolla Pharmaceutical		$5.73	$3.07 ▼ $6.24	$155.11M	2.39	158,476 shs	66,708 shs
RLAY Relay Therapeutics	$3.22 -6.7%	$2.96	$1.78 ▼ $10.72	$552.05M	1.59	2.08 million shs	2.02 million shs
TSHA Taysha Gene Therapies	$2.54 -4.2%	$2.18	$1.05 ▼ $4.07	$545.24M	1.04	3.09 million shs	2.46 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	0.00%	-9.40%	+64.34%	+13.37%	-51.15%
LJPC La Jolla Pharmaceutical	0.00%	0.00%	0.00%	0.00%	0.00%
RLAY Relay Therapeutics	0.00%	-4.17%	+15.41%	-12.02%	-58.93%
TSHA Taysha Gene Therapies	0.00%	-10.56%	-0.78%	+47.67%	-35.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUTL Autolus Therapeutics	2.5585 of 5 stars	3.5	1.0	0.0	0.0	2.6	3.3	0.6
LJPC La Jolla Pharmaceutical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	2.204 of 5 stars	3.4	2.0	0.0	0.0	1.4	2.5	0.6
TSHA Taysha Gene Therapies	3.7992 of 5 stars	4.5	1.0	0.0	0.0	3.3	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	3.00	Buy	$9.32	339.62% Upside
LJPC La Jolla Pharmaceutical	0.00	N/A	N/A	N/A
RLAY Relay Therapeutics	2.83	Moderate Buy	$17.67	448.65% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$7.57	198.09% Upside

Current Analyst Ratings Breakdown

Latest LJPC, AUTL, RLAY, and TSHA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/10/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/3/2025	TSHA Taysha Gene Therapies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $11.00
6/2/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $8.00
5/29/2025	TSHA Taysha Gene Therapies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/29/2025	TSHA Taysha Gene Therapies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$5.00 ➝ $6.00
5/29/2025	TSHA Taysha Gene Therapies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $9.00
5/16/2025	TSHA Taysha Gene Therapies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$8.00 ➝ $9.00
5/7/2025	RLAY Relay Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $10.00
4/28/2025	TSHA Taysha Gene Therapies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00 ➝ $5.00
4/28/2025	TSHA Taysha Gene Therapies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$7.00 ➝ $7.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$9.01M	62.61	N/A	N/A	$0.64 per share	3.31
LJPC La Jolla Pharmaceutical	$75.72M	0.00	N/A	7.95	($2.94) per share	0.00
RLAY Relay Therapeutics	$7.68M	71.89	N/A	N/A	$5.90 per share	0.55
TSHA Taysha Gene Therapies	$7.22M	75.48	N/A	N/A	$0.40 per share	6.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$208.38M	-$0.88	N/A	N/A	N/A	N/A	-63.65%	-36.54%	8/14/2025 (Estimated)
LJPC La Jolla Pharmaceutical	$19.66M	$0.12	51.84	0.00	N/A	8.54%	-5.46%	4.00%	N/A
RLAY Relay Therapeutics	-$341.97M	-$2.23	N/A	N/A	N/A	N/A	-45.75%	-40.75%	8/5/2025 (Estimated)
TSHA Taysha Gene Therapies	-$111.57M	-$0.34	4.03	N/A	N/A	-229.67%	-106.36%	-49.16%	8/11/2025 (Estimated)

Latest LJPC, AUTL, RLAY, and TSHA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	TSHA Taysha Gene Therapies	-$0.08	-$0.08	N/A	-$0.08	$1.48 million	$2.30 million
5/8/2025	Q1 2025	AUTL Autolus Therapeutics	-$0.24	-$0.26	-$0.02	-$0.26	$1.59 million	$8.98 million
5/5/2025	Q1 2025	RLAY Relay Therapeutics	-$0.50	-$0.46	+$0.04	-$0.46	$0.01 million	$7.68 million
3/20/2025	Q4 2024	AUTL Autolus Therapeutics	-$0.21	-$0.09	+$0.12	-$0.09	$2.98 million	$0.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
LJPC La Jolla Pharmaceutical	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	N/A	13.69	13.69
LJPC La Jolla Pharmaceutical	N/A	4.02	3.52
RLAY Relay Therapeutics	N/A	18.42	18.42
TSHA Taysha Gene Therapies	0.48	5.51	5.51

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
LJPC La Jolla Pharmaceutical	97.06%
RLAY Relay Therapeutics	96.98%
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
LJPC La Jolla Pharmaceutical	36.30%
RLAY Relay Therapeutics	4.87%
TSHA Taysha Gene Therapies	3.78%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	330	266.14 million	197.71 million	Optionable
LJPC La Jolla Pharmaceutical	61	24.94 million	15.89 million	Optionable
RLAY Relay Therapeutics	330	171.45 million	160.15 million	Optionable
TSHA Taysha Gene Therapies	180	214.66 million	199.41 million	Optionable

LJPC, AUTL, RLAY, and TSHA Headlines

Recent News About These Companies

Millennium Management LLC Makes New Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

June 12 at 3:07 AM | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Earns Buy Rating from Needham & Company LLC

June 12 at 1:19 AM | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 10.5% - Time to Buy?

June 11, 2025 | marketbeat.com

Cantor Fitzgerald Estimates TSHA FY2026 Earnings

June 11, 2025 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 5.9% - What's Next?

June 10, 2025 | marketbeat.com

Needham & Company LLC Reaffirms "Buy" Rating for Taysha Gene Therapies (NASDAQ:TSHA)

June 10, 2025 | marketbeat.com

Taysha Gene Therapies Grants Stock Options to New Employees Under Inducement Plan

June 8, 2025 | nasdaq.com

Wellington Management Group LLP Purchases 122,402 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

June 7, 2025 | marketbeat.com

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 6, 2025 | globenewswire.com

Squarepoint Ops LLC Has $366,000 Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

June 6, 2025 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up After Insider Buying Activity

June 6, 2025 | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $11.00 at Canaccord Genuity Group

June 5, 2025 | americanbankingnews.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Major Shareholder Buys $2,062,500.00 in Stock

June 5, 2025 | marketbeat.com

Taysha Gene Therapies Releases TSHA-102 Clinical Program Updates

June 4, 2025 | insidermonkey.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up on Insider Buying Activity

June 4, 2025 | marketbeat.com

Retail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial Data

June 4, 2025 | msn.com

Paul B. Manning Buys 750,000 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Stock

June 4, 2025 | insidertrades.com

Taysha Gene Therapies Highlights TSHA-102 Program Advancements for Rett Syndrome at 2025 IRSF Scientific Meeting

June 3, 2025 | quiverquant.com

Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program

June 3, 2025 | globenewswire.com

Taysha Gene Therapies (NASDAQ:TSHA) Given "Buy" Rating at Needham & Company LLC

June 3, 2025 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $11.00

June 3, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LJPC, AUTL, RLAY, and TSHA Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$2.12 -0.03 (-1.40%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$2.12 +0.00 (+0.24%)

As of 06/13/2025 07:46 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

La Jolla Pharmaceutical NASDAQ:LJPC

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.

Relay Therapeutics NASDAQ:RLAY

$3.22 -0.23 (-6.67%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$3.26 +0.04 (+1.21%)

As of 06/13/2025 06:24 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Taysha Gene Therapies NASDAQ:TSHA

$2.54 -0.11 (-4.15%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$2.55 +0.01 (+0.39%)

As of 06/13/2025 07:51 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time